In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a price target of $5.00.
Roy Buchanan has given his Buy rating due to a combination of factors including AN2 Therapeutics’ strategic efforts to advance its pipeline and the potential of its lead candidate, epetraborole. The company is preparing for a critical FDA meeting in the first half of 2025 to discuss the Phase 2 results of epetraborole, which targets refractory MAC NTM infections. Despite some challenges in efficacy, the drug showed significant improvement in a key quality of life measure, suggesting potential for future success.
Additionally, AN2 Therapeutics is progressing with its preclinical candidate for Chagas disease and is planning a Phase 1 trial by mid-2025. The company’s financial health is robust, with a cash runway extending through 2027, allowing it to continue its research and development activities. These elements combine to create a positive outlook for the company’s growth and development prospects, justifying the Buy rating.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
AN2 Therapeutics, Inc. (ANTX) Company Description:
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
